Pfizer Announces Agreement with Puma Biotechnology and Lyrica Success

Pfizer have announced an agreement with Puma Biotechnology for the development and commercialization of neratinib, an investigational oral, multi-targeted inhibitor of the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases.  The drug, which shows promise as a treatment for breast cancer, is being studied in the neoadjuvant, adjuvant and advanced settings in HER2/ErbB2 positive breast

Continue Reading